BIOGEN INC
For the period ended Dec 31, 2023. Filed Feb 14, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 14, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
RULE 10b5-1 TRADING ARRANGEMENTS
From time to time, our officers (as defined in Rule 16a-1(f)) and directors may enter into Rule 10b5-1 or non-Rule 10b5-1 trading arrangements (as each such term is defined in Item 408 of Regulation S-K). During the fourth quarter of 2023 our officers and directors took the following actions with respect to 10b5-1 trading arrangements:
| Trading Arrangement | ||||||
|---|---|---|---|---|---|---|
| Name and Position | Action | Date | Rule10b5-1 | Non-Rule 10b5-1 | Total Shares to be Sold | Expiration Date |
| Robin Kramer (Senior Vice President, Chief Accounting Officer) | Adopt | 11/13/2023 | X | — | 1,500 | 11/10/2025 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.